Sangamo Therapeutics Newsroom

Truist Financial Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating

Moomoo NewsOct 24 06:41 ET

TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating

Moomoo NewsOct 24 01:32 ET

A Quick Look at Today's Ratings for Sangamo Therapeutics(SGMO.US), With a Forecast Between $1 to $5

Moomoo NewsOct 23 09:09 ET

Sangamo Therapeutics Analyst Ratings

BenzingaOct 22 12:27 ET

Sangamo Therapeutics Analyst Ratings

BenzingaAug 22 09:07 ET

H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsAug 22 06:33 ET

RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)

TipRanksAug 7 07:28 ET

Sangamo Therapeutics Analyst Ratings

BenzingaJul 31 08:39 ET

H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsJul 31 06:33 ET

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target

BenzingaJul 24 15:23 ET

Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know

BenzingaMay 15 11:04 ET

Sangamo Therapeutics Analyst Ratings

BenzingaMay 15 10:34 ET

Sangamo Therapeutics Analyst Ratings

BenzingaMar 19 06:27 ET

Sangamo Therapeutics Analyst Ratings

BenzingaMar 14 12:01 ET

Sangamo Therapeutics Analyst Ratings

BenzingaMar 13 12:52 ET

Sangamo Therapeutics Analyst Ratings

BenzingaFeb 12 12:46 ET

Sangamo Therapeutics Analyst Ratings

BenzingaFeb 6 08:46 ET

Sangamo Therapeutics Analyst Ratings

BenzingaJan 19 06:57 ET

Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target

BenzingaNov 6, 2023 08:21 ET

Sangamo Therapeutics Analyst Ratings

BenzingaNov 6, 2023 08:19 ET